Background
==========

Osteomalacia (OM) represents a metabolic disorder characterized by decreased mineralization of mature bone. Multiple causes underline this abnormality including inborn errors, chronic kidney disease and insufficient levels of vitamin D or calcium ([@bib1]). Phosphaturic mesenchymal tumor (PMT) is an uncommon cause of osteomalacia, usually manifests as a solitary benign neoplasm. Most of the tumors are located either in bone or soft tissue ([@bib2]). The tumors are common in middle age individuals, although the age range may vary considerably with male to female ratio of 1.2:1 ([@bib3], [@bib4]).

The clinical symptoms are vague. Therefore, diagnosis may last for up to 10 years. Weidner and Santa Cruz coined the term PMT in 1987. One of the clinical features of PMT is tumor-induced osteomalacia (TIO) characterized by bone pain, muscle weakness and pathological fractures; others may be without symptoms and only laboratory tests may disclose hypophosphatemia and hyperphosphaturia ([@bib5]). Increased levels of fibroblast growth factor 23 (FGF23) and relative hyperphosphaturia in the presence of hypophosphatemia are important clues for suspecting PMT ([@bib6]). Different imaging modalities are essential for tumor localizations. Surgery is curative and a wide resection with negative margins is of major importance for preventing recurrence ([@bib7]).

PMT among elderly patients is relatively rare. The aim of this article is to report a case of PMT with extremely rare localization in a patient 81 years old and to review the literature focusing on published data regarding this entity among elderly patients.

Case presentation
=================

An 81-year-old man was referred in 2014 to our clinic due to osteopenia with T score of −1.5 in the spine and −1.2 in the femur. He was treated previously by his family physician for 5 years with alendronate, vitamin D and calcium. In 2011, he was referred to orthopedic consultation for left hip pain. His physical examination and pelvic CT were normal. Medical history did not disclose any chronic diseases or hereditary bone disease apart from old bullet fragments in different body sites.

Investigation
=============

Laboratory results since 2004 disclosed normal calcium levels 9.9 mg/dL (normal range: 8.8--10.20 mg/dl), low blood phosphorus 2.10 mg/dL (normal range: 2.5--5 mg/dL), mild elevated alkaline phosphatase 144 U/L (normal range: 30--120 U/L), normal level of 25 hydroxyvitamin D 121 nmol/l. Quantitative determination of 1,25 dihydroxyvitamin D (1,25(OH)2D) in serum revealed a normal level 99 pmol/L (normal range: 39--160 pmol/L) using DiaSorin LIAISON XL *in vitro* chemiluminescent immunoassay (CLIA) performed on the LIAISON XL Analyzer. Intact FGF-23 was elevated 150.8 pg/mL (normal range: 23.2--95.4 pg/mL) using the same method. Repeated 24-h urine phosphate collection disclosed relatively high phosphate excretion 959 mg/24 h (normal range: 400--1300 mg/24 h). For suspected PMT, ^68^Gallium DOTATATE PET/CT was performed and a pathological uptake in the upper aspect of the left shoulder adjacent to the coracoid process was observed. No mediastinal and axillary lymphadenopathy were observed ([Fig. 1](#fig1){ref-type="fig"}).Figure 168GA-DOTATATE PET/CT shows normal biodistribution in the PET 3D maximal intensity projection (C) with physiological uptake in the spleen, liver, kidneys and urinary bladder and pathological uptake in the left supraclavicular region (arrow). An axial slice at this level demonstrates a soft tissue nodule (arrow) on the CT portion of the study (A) that is located deep in the soft tissues, near the scapula, at the junction between the serratus anterior and supraspinatus muscles. The fusion axial image at this level (B) of the PET slice in color, and the CT slice beneath it in grayscale, demonstrates the high uptake in orange-purple in the nodule (arrow).

Treatment
=========

During his evaluation, the patient was treated ineffectively with potassium phosphate monobasic (Calciless) eight tablets daily and vitamin D 1000 IU. His blood phosphorus levels remained consistently low despite this treatment modality. According to above investigation, the patient was referred to the orthopedic surgical department and a guided ultrasound wide resection of the tumor was performed. Histopathological examination disclosed fat tissue with proliferation of bland spindle cells with numerous blood vessels, amorphous matrix deposition and few calcifications without atypia and mitosis. The margins were free of tumor. These findings were consistent with benign PMT ([Fig. 2](#fig2){ref-type="fig"}).Figure 2Fat tissue with proliferation of bland spindle cells, numerous blood vessels with amorphous matrix deposition and few calcifications without atypia and mitosis. The findings are consistent with benign phosphaturic mesenchymal tumor (stain, hematoxylin and eosin; original magnification, ×200).

Follow-up and outcome
=====================

Three months after surgery, his blood phosphorus levels and 24-h phosphorus urine collection were normalized without any treatment.

Discussion
==========

PMT represents a rare entity especially among elderly patients. The diagnosis is usually delayed due to multiple factors including vague signs and symptoms, difficulty in tumor localization and histological identification.

PMTs secrete proteins such as FGF-23, FGF-7, frizzeled-related protein 4 and matrix extracellular phosphoglycoprotein ([@bib8]). FGF-23 represents the only clinically relevant protein among them, its main action is by inhibiting the sodium phosphate renal co-transporters and the suppression of 1α hydroxylase activity, causing decreased renal reabsorption and increased urinary phosphate excretion. As a result, in addition to hypophosphatemia, relative hyperphosphaturia, a decrease in 1,25 dihydroxyvitamin D are observed ([@bib2]). It is noteworthy that recent identification of a fusion fibronectin and fibroblast growth factor receptor 1 (FN/FGF-1) as a molecular abnormality in some tumors enhanced our knowledge in understanding not only the pathophysiological mechanisms underlying this entity, but also the transcriptional, translocational and posttranscriptional modifications, suggesting future approaches to target therapies ([@bib9]).

Tumor localization represents another obstacle during patient\'s evaluation. PMTs are slow-growing tumors and their localization is difficult. Octreotide scintigraphy, whole-body Tc-99m sestamibi scanning, 18F-flurodexyglucose positron emission tomography (FDG-PET), ^68^Gallium-conjugated somatostatin peptide analogs, such as ^68^Ga-DOTATATE PET/CT and ^68^Ga-DOTANOC PET/CT, whole-body MRI and CT are used for tumor localization. It is worthy of mention that ^68^Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity in comparison to Octreoscan SPECT/CT, FDG-PET and ^18^F FDG-PET for tumor localization in patients with TIO ([@bib10], [@bib11]). ^68^Ga-DOTATATE PET/CT was chosen for tumor localization in this case. The scan revealed pathological uptake measuring 1.3 cm in the upper aspect of left shoulder subcutaneously adjacent to the coracoid process. This very rare localization was challenging for orthopedic surgeons expert in this field using intraoperative ultrasonography for precise localization and wide excision.

About 404 cases of oncogenic osteomalacia have been reported of which PMTs are the most frequent. Both genders are equally affected and most patients are between the ages of 30 and 40 years. The most common localization of PTM involves the extremities (95%) followed by head and neck sites (5%). Most of PMTs are localized in the lower extremities ([@bib12]).

A PubMed search between the years 1990 and 2018 has been conducted using the terms 'phosphaturic mesenchymal tumor', 'tumor-induced osteomalacia' and 'oncogenic osteomalacia'. Our search focused on reported cases among elderly patients age ≥70 years, tumor localization, the presence or absence of signs and symptoms such as bone pain, muscle weakness and pathological fractures as well.

We had identified 33 cases with PMTs among elderly patients age ≥70 years old with mean age (mean age 77.2 years), the female-to-male ratio was 1.35:1. Of these, 14 cases (42.4 %) with tumor localization in the pelvis and lower extremity, 14 cases (42.4%) in the head, neck and upper limb, of which ten cases (33.3%) with tumor localized in the head and neck, the remaining four cases (16.2%), the tumor was localized in other sites such as mediastinum, abdominal wall and spine. Unlike previously reported data -- where tumor localization was predominantly in the lower extremities -- our search demonstrated that PMTs among elderly patients are present at a higher rate in the head and neck and with equal number of cases in the pelvis and lower extremities as well as in the head, neck and upper limb ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Table 1Elderly patient characteristics with phosphaturic mesenchymal tumor.Authors and year of publicationNo. of casesAgeSexSite of tumorSigns and symptomsPark *et al*. (13)176FHumerusNABaronofsky *et al*. (14)172FAcetabulumRt. Hip painFolpe *et al*. (4)473MHipNA71FForearm77FAbdominal wall80MIschiumDupond *et al*. (15)171MMandible leftBone pain and muscle weaknessVollbrecht *et al*. (16)187MThird metacarpalMyalgiaKenealy *et al*. (17)379FEthmoid sinus ltHip fracture70MExtradural ltHip fracture70FIschiumSkeletal painYun *et al*. (18)171FMandible lower with neck extensionItching sensation, kyphosis and distorted arms and legsSavage and Zimmer (19)173FPterygopalatine fossaLeg pain, walking difficulties, fracture of ribs and footShelekhova *et al*. (20)170FSinonasal cavityNABauer *et al*. (21)271FFirst toe of the left footFractures multiple sites and osteoarthritis of the hip77MParotid gland leftBack pain and hip fracture leftFok *et al*. (22)174MSoft tissue mass plantar surface adjacent to left second metatarsal headLimb pain left lower, proximal myopathyWémeau *et al*. (23)186Fsub maxillaryRib and vertebral fractureWesterberg *et al*. (24)173FSole of the right for footMultiple site fractures and muscle weaknessSyed *et al*. (25)171FTemporal bone (middle ear and mastoid)Hearing loss, facial nerve palsyFatani *et al*. (26)381MFemoral neckBone pain and fractures76FGreat toe87FC2Ledford *et al*. (27)174MCalcaneusBone pain, muscle weakness, fractures (lumbar, vertebral and pelvis)Honda *et al*. (28)173MNeckFemur metastasis\
Bon pain, proximal muscle weaknessAizawa *et al*. (29)172MC5WeaknessJerkovich *et al*. (30)170F3rd metacarpal bone left handDiffuse bone pain\
MyalgiaTajima *et al*. (31)177MLeft parotid glandNALee *et al*. (32)173MFemurRefractory bone pain and muscle weaknessPaul *et al*. (33)274FRight footBone pain, proximal muscle weakness72FDistal end of right femurBone painGambhir (34)170MSuperior mediastinum at D1/D2 levelsNAChazal *et al*. (35)170FSecond phalanges right footMultiple fractures and diffuse pain Table 2Tumor localization according to different regions.Localization of primary tumorTotal numberSex F/MHead and neck106/4Upper limb42/2Lower limb and pelvis147/7Others (mediastinum, abdomen and spine)52/3Total number of patients3317/16

In the case presented in this manuscript, the tumor was located in the upper aspect of the left shoulder adjacent to the coracoid process. To the best of our knowledge, this tumor localization was unique and the first to be reported in the literature. Furthermore, surgical resection was challenging for the surgeon and guided intraoperative ultrasonography was used in order to perform a successful wide resection.

Conclusions
===========

The diagnosis of PMTs should be considered among elderly patients presented with osteomalacia. Reviewing the literature, head and neck tumor localization is frequent among this group of patients and should be taken into account. Performing wide resection of the tumor represents an important matter for cure and preventing recurrence.
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